









Markets
/
Stocks
/
nasdaq-fhtx
/

Foghorn Therapeutics Inc.

FHTX

5.680USD

+0.450+8.60%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

321.16MMarket Cap

LossP/E TTM



Foghorn Therapeutics Inc.

5.680

+0.450+8.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Foghorn Therapeutics Inc.

Currency: USD Updated: 2026-02-06

Key Insights

Foghorn Therapeutics Inc.'s fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.33.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Foghorn Therapeutics Inc.'s Score

Industry at a Glance

Industry Ranking

71 / 392

Overall Ranking

191 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Foghorn Therapeutics Inc. Highlights

StrengthsRisks

Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 17.55% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 22.60M.

Undervalued

The company’s latest PE is -5.03, at a low 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 3.15K shares of this stock.

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

11.333

Target Price

+101.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Foghorn Therapeutics Inc. is 7.58, ranking 97 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 8.15M, representing a year-over-year increase of 4.42%, while its net profit experienced a year-over-year increase of 17.12%.

Score

Industry at a Glance

Previous score

7.58

Change



Financials

5.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.21

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Foghorn Therapeutics Inc.'s Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Foghorn Therapeutics Inc. is 6.52, ranking 259 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.03, which is -76.30% below the recent high of -1.19 and -17.61% above the recent low of -5.92.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Foghorn Therapeutics Inc. is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 14.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Strong Buy

Current Rating

11.333

Target Price

+101.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Foghorn Therapeutics Inc.

FHTX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Foghorn Therapeutics Inc. is 6.84, ranking 155 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.74 and the support level at 4.83, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.179

Neutral

RSI(14)

51.126

Neutral

STOCH(KDJ)(9,3,3)

39.935

Buy

ATR(14)

0.375

Low Volatility

CCI(14)

-101.901

Sell

Williams %R

54.751

Neutral

TRIX(12,20)

0.274

Sell

StochRSI(14)

73.720

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.616

Buy

MA10

5.714

Sell

MA20

5.885

Sell

MA50

5.269

Buy

MA100

4.877

Buy

MA200

4.894

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Foghorn Therapeutics Inc. is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.66%, representing a quarter-over-quarter decrease of 0.30%. The largest institutional shareholder is The Vanguard, holding a total of 1.93M shares, representing 3.29% of shares outstanding, with 0.06% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Flagship Ventures

12.67M

Fidelity Management & Research Company LLC

5.47M

-1.06%

BVF Partners L.P.

5.30M

Eli Lilly and Company

4.00M

Kadoch (Cigall)

3.65M

+0.79%

Deerfield Management Company, L.P.

3.26M

Raymond James & Associates, Inc.

2.46M

+4.02%

The Klarman Family Foundation

2.14M

BlackRock Institutional Trust Company, N.A.

2.07M

+1.41%

The Vanguard Group, Inc.

Star Investors

1.90M

+0.78%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Foghorn Therapeutics Inc. is 2.70, ranking 210 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 3.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.